Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.   16 September 2021
Americas
Allergan has struck a deal with two generic manufacturers to resolve a long-running patent infringement suit over its antidepressant drug Fetzima.   16 September 2021
Americas
The US Food and Drug Administration has urged the US Patent and Trademark Office (USPTO) to curb drug costs in the wake of President Joe Biden’s plan to promote competition in the pharmaceutical sector.   14 September 2021
Big Pharma
Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza.   13 September 2021
Americas
Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz.   9 September 2021
Big Pharma
Australia will waive IP protections for COVID-19 vaccines to enable more cost-effective copycat versions to be manufactured in developing countries, in the wake of mounting pressure from human rights groups and governments worldwide.   9 September 2021
Medtech
Advanced Biologics has managed to convince the English High Court to expedite a patent infringement and validation suit it is embroiled in with German rival Med-El.   9 September 2021
Plant Varieties
International law firm Haynes Boone has launched the CBD Hemp Industry Group to advise businesses on the burgeoning cannabinoid market.   8 September 2021
Americas
Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen.   7 September 2021
Americas
Teva Pharmaceuticals has abandoned its lawsuit against Amicus Therapeutics, which it had accused of contravening a US federal law designed to help generic makers bring cost-effective biosimilars to market.   7 September 2021